CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
Penguin Cold Capdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05961215
NCT05961215N/ACompleted
CompareCT.gov

IIT2023-03-Vescio-ColdCap: Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma

Cedars-Sinai Medical Center·interventional·Posted Jul 27, 2023·Updated Oct 27, 2025

In Brief

A clinical study evaluating Penguin Cold Cap for Multiple Myeloma. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This pilot study of scalp cooling with Penguin cold caps will examine the effectiveness of scalp cooling to reduce the development of hair loss in 30 participants with multiple myeloma undergoing high-dose chemotherapy with melphalan and autologous peripheral blood stem cell transplant at Cedars-Sinai Medical Center. The investigators will also assess the potential impact of hair loss versus the discomfort and inconvenience of the scalp cooling procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsPenguin Cold Caps

Timeline

N/ACompletedFinished
202420252026
First PostedJul 27, 2023
Enrollment StartAug 10, 2023
Primary CompletionNov 1, 2024
Study CompletionFeb 3, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.9 years ago

Interventions

Penguin Cold Capdevice

Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.